CELC
Price
$12.45
Change
+$0.45 (+3.75%)
Updated
Dec 20, 04:59 PM (EDT)
87 days until earnings call
KANT
Price
$0.41
Change
-$0.01 (-2.38%)
Updated
Dec 20 closing price
Ad is loading...

CELC vs KANT

Header iconCELC vs KANT Comparison
Open Charts CELC vs KANTBanner chart's image
Celcuity
Price$12.45
Change+$0.45 (+3.75%)
Volume$8.06K
CapitalizationN/A
Kineta
Price$0.41
Change-$0.01 (-2.38%)
Volume$17.81K
CapitalizationN/A
CELC vs KANT Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KANT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. KANT commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Hold and KANT is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (CELC: $12.46 vs. KANT: $0.41)
Brand notoriety: CELC and KANT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 446% vs. KANT: 41%
Market capitalization -- CELC: $462.63M vs. KANT: $5.06M
CELC [@Biotechnology] is valued at $462.63M. KANT’s [@Biotechnology] market capitalization is $5.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileKANT’s FA Score has 1 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • KANT’s FA Score: 1 green, 4 red.
According to our system of comparison, both CELC and KANT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 5 TA indicator(s) are bullish while KANT’s TA Score has 3 bullish TA indicator(s).

  • CELC’s TA Score: 5 bullish, 3 bearish.
  • KANT’s TA Score: 3 bullish, 8 bearish.
According to our system of comparison, CELC is a better buy in the short-term than KANT.

Price Growth

CELC (@Biotechnology) experienced а -0.48% price change this week, while KANT (@Biotechnology) price change was -45.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

CELC is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($463M) has a higher market cap than KANT($5.06M). CELC YTD gains are higher at: -14.482 vs. KANT (-88.642). KANT has higher annual earnings (EBITDA): -20.45M vs. CELC (-85.45M). CELC has more cash in the bank: 264M vs. KANT (900K). KANT has less debt than CELC: KANT (710K) vs CELC (97.2M). CELC (0) and KANT (0) have equivalent revenues.
CELCKANTCELC / KANT
Capitalization463M5.06M9,156%
EBITDA-85.45M-20.45M418%
Gain YTD-14.482-88.64216%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M900K29,333%
Total Debt97.2M710K13,690%
FUNDAMENTALS RATINGS
CELC vs KANT: Fundamental Ratings
CELC
KANT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
29
Undervalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
7793
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KANT's Valuation (29) in the null industry is in the same range as CELC (40) in the Miscellaneous Commercial Services industry. This means that KANT’s stock grew similarly to CELC’s over the last 12 months.

CELC's Profit vs Risk Rating (86) in the Miscellaneous Commercial Services industry is in the same range as KANT (100) in the null industry. This means that CELC’s stock grew similarly to KANT’s over the last 12 months.

CELC's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as KANT (100) in the null industry. This means that CELC’s stock grew similarly to KANT’s over the last 12 months.

CELC's Price Growth Rating (77) in the Miscellaneous Commercial Services industry is in the same range as KANT (93) in the null industry. This means that CELC’s stock grew similarly to KANT’s over the last 12 months.

CELC's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as KANT (100) in the null industry. This means that CELC’s stock grew similarly to KANT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCKANT
RSI
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
88%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
84%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 29 days ago
83%
Bullish Trend 18 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
82%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KANT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CAL23.531.08
+4.81%
Caleres
SMBK31.480.12
+0.38%
SmartFinancial
IONS35.630.04
+0.11%
Ionis Pharmaceuticals
RSG203.73-0.22
-0.11%
Republic Services
GP0.75-0.02
-2.33%
GreenPower Motor Company

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with ABOS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+3.83%
ABOS - CELC
42%
Loosely correlated
+2.78%
SNDX - CELC
42%
Loosely correlated
+1.79%
PLRX - CELC
41%
Loosely correlated
-0.68%
ALLO - CELC
40%
Loosely correlated
+1.63%
NAUT - CELC
40%
Loosely correlated
-2.22%
More

KANT and

Correlation & Price change

A.I.dvisor indicates that over the last year, KANT has been loosely correlated with MDGL. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if KANT jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KANT
1D Price
Change %
KANT100%
-1.83%
MDGL - KANT
62%
Loosely correlated
+5.12%
VRPX - KANT
48%
Loosely correlated
+4.30%
SLNO - KANT
45%
Loosely correlated
-0.04%
VKTX - KANT
35%
Loosely correlated
+1.83%
CELC - KANT
34%
Loosely correlated
+3.83%
More